We specialize in supporting client decisions in clinical trials and drug development in the field of immunology. Through our vast collection of research and model components, we can apply pre-built model components to your project, build novel models, or license our technology for your model development and prediction needs.
Immunetrics has a suite of core modeling components (individual immune cells, organ systems, and biological processes) that can be used independently for modeling analyses and/or combined with other components to support new disease states or conditions. Models are constantly evolving as new research is published, and are typically customized to meet specific client goals.
|
Immunology |
Physiology |
Critical Care |
|
TH1/2/17/22 Tregs CD8+ T cells
Monocytes/Macrophages Neutrophils Eosinophils Mast cells Endothelial cells Epithelial cells Keratinocytes |
Cardiovascular system Renal system Pulmonary system Skin Joints |
Inflammation Coagulation/Bleeding Trauma
|
- Core models can be recombined to rapidly develop and customize patient-level models of many disease states
- Interested in a disease area or cell not mentioned on our website? Contact Us
Disease Specific Models
Immunetrics’ disease models span across acute inflammation, chronic, autoimmune conditions, and immuno-oncology. These models can be customized to meet specific needs and are constantly evolving to support new research outcomes. Disease Models Key Outputs Supported Therapeutics Rheumatoid Arthritis Swollen/tender joint counts (SJC/TJC) ACR20/50/70/90 DAS28(3)-CRP/ESR Low disease activity Remission Serum cytokines and biomarkers Serum cell counts MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies Psoriatic Arthritis / Psoriasis Swollen/tender joint counts ACR20/50/70 DAS28(3)-CRP/ESR PASI 50/75/90/100 Serum cytokines and biomarkers Serum cell counts MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-IL12/23 Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies Ulcerative Colitis Mayo score Response/Remission Mucosal healing Serum cytokines and biomarkers MTX 5-ASA Corticosteroids Anti-TNFs JAK inhibitors S1P receptor antagonist Best Overall Response (BOR) based on bone marrow and blood blast counts: Response vs Non-response Minimal Residual Disease (MRD = < 0.1% Blasts) Death Duration of Response (DoR) Relapse Disease-specific Biomarkers: Hypomethylating Agents (i.e. azacytidine) Chemotherapies (cytarabine) BCL-2 inhibitor (venetoclax) Monoclonal antibodies (e.g. anti-CD47) Best Overall Response (BOR) based on M-protein changes: Overall Response Rate (ORR) Time To Response (TTR) Duration of Response (DoR) Disease-specific Biomarkers: Immunomodulatory Drugs (IMiDs) Antibody-Drug Conjugates (ADCs) Immune Cell Engagers (NK and T cell Engagers) Monoclonal Antibodies (e.g. Daratumumab) Chimeric Antigen Receptor T cell Therapies (CAR T therapies) Steroids (i.e. Dexamethasone) Tumor Size Best Overall Response (BOR) Percent change in Tumor Diameter Best Overall Response (BOR) Progressive Disease (PD) Stable Disease (SD) Responders (RR) Monoclonal Antibodies Chemotherapies Complete Responder (CR) Partial Responder (PR) Tumor Cell Number Chimeric Antigen Receptor T cell Therapies (CAR T therapies) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) Immunomodulatory Drugs (IMiDs) Sepsis Multi-Organ Dysfunction Mean arterial pressure (MAP) Central venous pressure (CVP) Blood oxygen saturation (O2sat) Breathing frequency Tidal volume Blood gases (PaO2, PaCO2) Creatinine Urinary output (UOP) Coagulation proteins Fluid therapy Vasopressors Ventilators Diuretics Dialysis Antibiotics Trauma Cytokines Immune cells Coagulation proteins Blood loss Mean arterial pressure (MAP) Blood oxygen saturation (O2sat) Fluid therapies Blood products Ventilators * Indicates models developed internally OR for a specific purpose. These models are currently limited in functionality compared to our platform models.
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)
Melanoma*
Client Proprietary
Non-small cell lung cancer (NSCLC)*
Diffuse large B cell lymphoma
(DLBCL)*